标签归档：lxw

LXW7 TFA

发表于由

LXW7 TFA; 纯度: 99.17%

LXW7 TFA 是一种含 Arg-Gly-Asp (RGD) 的环状肽，是一种整合素 αvβ3 抑制剂，对 αvβ3 整联蛋白具有很高的结合亲和力，IC50 为 0.68 μM。LXW7 TFA 可增强 VEGFR-2 磷酸化和 ERK1/2 活化。具有抗炎活性。

LXW7 TFAamp;;

LXW7 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥13500 In-stock
5 mg ￥28000 In-stock
10 mg ￥38000 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

LXW7 TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Macrocyclic Compound Library
  • Peptide Library

生物活性

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].

IC50 Target

IC50: 0.68 μM (αvβ3 integrin)[1]
体外研究
(In Vitro)

LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery[1].
LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)[3]
Dosage: 100 μg/kg
Administration: Intravenous injection
Result: Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.

分子量

934.92

Formula

C31H49F3N12O14S2
Sequence

Cys-Gly-Arg-Gly-Asp-Asp-Val-Cys-NH2 (Disulfide bridge:Cys1-Cys8)
Sequence Shortening

CGRGDDVC-NH2 (Disulfide bridge:Cys1-Cys8)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Xiao W, et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther. 2010 Oct;9(10):2714-23.

    [2]. Hao D, et al. Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. ACS Chem Biol. 2017 Apr 21;12(4):1075-1086.

    [3]. Fang T, et al. LXW7 ameliorates focal cerebral ischemia injury and attenuates inflammatory responses in activated microglia in rats. Braz J Med Biol Res. 2016 Aug 1;49(9):e5287.

LXW7

发表于由

LXW7;

LXW7 是一种含 Arg-Gly-Asp (RGD) 的环状肽，是一种整合素 αvβ3 抑制剂，对 αvβ3 整联蛋白具有很高的结合亲和力，IC50 为 0.68 μM。LXW7 可增强 VEGFR-2 磷酸化和 ERK1/2 活化。具有抗炎活性。

LXW7amp;;

LXW7 Chemical Structure

CAS No. : 1313004-77-1

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

LXW7 的其他形式现货产品:

LXW7 TFA

生物活性

LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].

IC50 Target

IC50: 0.68 μM (αvβ3 integrin)[1]
体外研究
(In Vitro)

LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery[1].
LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)[3]
Dosage: 100 μg/kg
Administration: Intravenous injection
Result: Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.

分子量

820.89

Formula

C29H48N12O12S2
CAS 号

1313004-77-1
Sequence Shortening

CGRGDDVC-NH2 (Disulfide bridge:Cys1-Cys8)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Xiao W, et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther. 2010 Oct;9(10):2714-23.

    [2]. Hao D, et al. Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. ACS Chem Biol. 2017 Apr 21;12(4):1075-1086.

    [3]. Fang T, et al. LXW7 ameliorates focal cerebral ischemia injury and attenuates inflammatory responses in activated microglia in rats. Braz J Med Biol Res. 2016 Aug 1;49(9):e5287.